Change in spinal bone mineral density as estimated by Hounsfield units following osteoporosis treatment with romosozumab, teriparatide, denosumab, and alendronate: an analysis of 318 patients

特立帕肽 医学 德诺苏马布 骨质疏松症 霍恩斯菲尔德秤 骨矿物 内科学 泌尿科 外科 计算机断层摄影术
作者
Anthony L. Mikula,Nikita Lakomkin,Abdelrahman M. Hamouda,Megan C. Everson,Zach Pennington,Rahul Robaish Kumar,Zachariah W. Pinter,Michael L. Martini,Mohamad Bydon,Kurt A. Kennel,Francis I. Baffour,Ahmad Nassr,Brett A. Freedman,Arjun S. Sebastian,Kingsley Abode-Iyamah,Paul A. Anderson,Jeremy L. Fogelson,Benjamin D. Elder
出处
期刊:Journal of neurosurgery [Journal of Neurosurgery Publishing Group]
卷期号:: 1-7 被引量:1
标识
DOI:10.3171/2024.4.spine2424
摘要

OBJECTIVE The purpose of this study was to determine the effect of osteoporosis medications on opportunistic CT-based Hounsfield units (HU). METHODS Spine and nonspine surgery patients were retrospectively identified who had been treated with romosozumab for 3 to 12 months, teriparatide for 3 to 12 months, teriparatide for > 12 months, denosumab for > 12 months, or alendronate for > 12 months. HU were measured in the L1–4 vertebral bodies. One-way ANOVA was used to compare the mean change in HU among the five treatment regimens. RESULTS In total, 318 patients (70% women) were included, with a mean age of 69 years and mean BMI of 27 kg/m 2 . There was a significant difference in mean HU improvement (p < 0.001) following treatment with romosozumab for 3 to 12 months (n = 32), teriparatide for 3 to 12 months (n = 30), teriparatide for > 12 months (n = 44), denosumab for > 12 months (n = 123), and alendronate for > 12 months (n = 100). Treatment with romosozumab for a mean of 10.5 months significantly increased the mean HU by 26%, from a baseline of 85 to 107 (p = 0.012). Patients treated with teriparatide for > 12 months (mean 23 months) experienced a mean HU improvement of 25%, from 106 to 132 (p = 0.039). Compared with the mean baseline HU, there was no significant difference after treatment with teriparatide for 3 to 12 months (110 to 119, p = 0.48), denosumab for > 12 months (105 to 107, p = 0.68), or alendronate for > 12 months (111 to 113, p = 0.80). CONCLUSIONS Patients treated with romosozumab for a mean of 10.5 months and teriparatide for a mean of 23 months experienced improved spinal bone mineral density as estimated by CT-based opportunistic HU. Given the shorter duration of effective treatment, romosozumab may be the preferred medication for optimization of osteoporotic patients in preparation for elective spine fusion surgery.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ding应助霸气的梦露采纳,获得10
1秒前
南方周末发布了新的文献求助10
2秒前
Tohka完成签到 ,获得积分10
3秒前
Goblin完成签到 ,获得积分10
3秒前
4秒前
Qu_Yun发布了新的文献求助10
6秒前
www完成签到 ,获得积分10
6秒前
花生完成签到 ,获得积分10
7秒前
Cao完成签到 ,获得积分10
9秒前
酷炫的毛巾应助雪宝宝采纳,获得10
9秒前
10秒前
12秒前
MOMO完成签到,获得积分10
12秒前
李善聪发布了新的文献求助20
13秒前
李健的小迷弟应助Alivelean采纳,获得10
13秒前
13秒前
CHENXIN532完成签到,获得积分10
13秒前
强风吹拂完成签到,获得积分10
14秒前
小满胜万全完成签到,获得积分10
14秒前
max完成签到,获得积分10
15秒前
tigger完成签到 ,获得积分10
15秒前
15秒前
16秒前
CHENXIN532发布了新的文献求助10
17秒前
18秒前
xiao_J发布了新的文献求助30
20秒前
立稳flag关注了科研通微信公众号
22秒前
ykxa完成签到,获得积分20
23秒前
26秒前
26秒前
明天好完成签到,获得积分10
26秒前
烟花应助科研通管家采纳,获得10
26秒前
科研通AI2S应助科研通管家采纳,获得10
26秒前
斯文败类应助科研通管家采纳,获得10
26秒前
pluto应助科研通管家采纳,获得20
26秒前
852应助科研通管家采纳,获得10
26秒前
26秒前
26秒前
26秒前
溫蒂完成签到,获得积分10
26秒前
高分求助中
【此为提示信息,请勿应助】请按要求发布求助,避免被关 20000
ISCN 2024 – An International System for Human Cytogenomic Nomenclature (2024) 3000
Continuum Thermodynamics and Material Modelling 2000
Encyclopedia of Geology (2nd Edition) 2000
105th Edition CRC Handbook of Chemistry and Physics 1600
Maneuvering of a Damaged Navy Combatant 650
Fashion Brand Visual Design Strategy Based on Value Co-creation 350
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 物理 生物化学 纳米技术 计算机科学 化学工程 内科学 复合材料 物理化学 电极 遗传学 量子力学 基因 冶金 催化作用
热门帖子
关注 科研通微信公众号,转发送积分 3777918
求助须知:如何正确求助?哪些是违规求助? 3323510
关于积分的说明 10214551
捐赠科研通 3038674
什么是DOI,文献DOI怎么找? 1667606
邀请新用户注册赠送积分活动 798207
科研通“疑难数据库(出版商)”最低求助积分说明 758315